- American City Business Journals•6 hours ago
A new biotech has launched in Waltham with a management team made up of former Biogen executives and $38 million in financing from Pfizer, former Genzyme CEO Henri Termeer and other prominent investors. Arrakis Therapeutics said it will focus on developing potential treatments for neurology, cancer and rare genetic disorders that target RNA, the all-important molecules that translate the instructions in DNA into proteins in the body. The $38 million Series A financing was led by California venture capital firm Canaan Partners.
- Motley Fool•4 days ago
The potential for ozanimod to reshape multiple sclerosis may be worth billions of dollars in annual sales.
- Motley Fool•5 days ago
Biogen's list price for a new rare-disease drug makes it one of the world's most expensive. Was that a mistake?
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||287.37 x 100|
|Ask||287.51 x 100|
|Day's Range||284.27 - 288.11|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|